Diabetes

Among midlife women participating in a large longitudinal study, certain phthalate metabolites were associated with higher diabetes incidence over 6 years — but only among white women, according to data published in The Journal of Clinical Endocrinology & Metabolism.

Fewer people with diabetes filled glucagon prescriptions in 2021 compared with 2011, though increases were seen among those with type 1 diabetes and adults with a history of severe hypoglycemia, according to study data.

For adults with prediabetes, vitamin D was effective in decreasing diabetes risk, according to results of a systematic review and meta-analysis published in Annals of Internal Medicine.

Findings from a meta-regression analysis indicated that the beneficial effects of SGLT2 inhibition on CV death and HF hospitalization in patients with diabetes may be related to body weight.

Researchers highlighted challenges with continuous glucose monitoring devices, including trouble interpreting results, device adhesion and smartphone access, among adults aged 50 to 85 years with type 1 or type 2 diabetes.

In a recent survey, nearly half of primary care patients with type 1 or type 2 diabetes reported suboptimal insulin use due to costs.

Among adults with diabetes who underwent PCI, rates of target lesion failure were similar for two drug-eluting stents, though net adverse clinical events varied between arms and differed for people taking insulin, data show.

Medicare Part B and Part D beneficiaries with diabetes who use insulin would have saved an average of $500 in 2020 if out-of-pocket insulin prices were capped at $35 that year, according to a report from HHS.

The benefits of type 1 diabetes screening have long been up for debate, but FDA approval of the first therapy to delay the disease’s onset may be changing the conversation.

A few months ago, I would have questioned the value of universal screening for type 1 diabetes because we did not have anything to offer people who are at risk for the disease. However, we now have a drug — teplizumab-mzwv — that can delay the onset of type 1 diabetes. That is an important advance.